What is the CEP 2.0? From the September 2023 this new CEP2.0 will be implemented. Manufacturer and the various organization want to know about what cep2.0 Cep2.0 is new look or the future cep. 1.What will change in the CEP2.0 As part of the implementation of the CEP 2.0, some changes are introduced, which affect […]
The FDA is proposing to establish norms for a non-prescription medication with an additional condition for non-prescription use (ACNU). If implemented, the proposed rule would establish requirements for a non-prescription drug product with an ACNU that an applicant must implement to ensure appropriate self-selection or appropriate actual use, or both, by consumers who are not […]
“The format of the cover letter attachment can be customized by the applicant according to their convenience. The primary purpose of the cover letter attachment is to assist applicants in ensuring that they address relevant information in any cover letter they submit to the FDA for the submissions mentioned in this guidance. The cover letter […]
INDUSTRY CONSULTATION ON ELECTRONIC COMMON TECHNICAL DOCUMENT (eCTD) IMPLEMENTATION IN SINGAPORE Overview HSA is planning to introduce eCTD to enable full e-submissions thereby minimising the need for submitting documents using storage media such as CD/DVD ROMs. HSA is working with our appointed vendor to develop the eCTD system (ICH eCTD version 3.2.2) in Singapore. The […]
Holders of an active medical device establishment licence (MDEL) must apply to have their licence reviewed every year before April 1 in order to continue doing business. Those with a suspended MDEL are exempt from applying. An annual licence review (ALR) ensures that MDEL holders are: Adhering to regulatory requirements Maintaining their licence information up […]
According to FDA regulations, if an applicant wishes to pursue approval of its Abbreviated New Drug Application (ANDA), applicant must submit all materials required to fully address all shortcomings in the Complete Response Letter (CRL) within one year of the CRL’s issuance. The applicant must submit a request for an extension on or before the […]
The Food and Drug Administration (FDA or Agency) is announcing the availability of a guidance for industry entitled “Revising abbreviated new drug applications (ANDAs) Labeling Following Revision of the reference listed drugs (RLDs).” In this guidance, FDA is providing information on How ANDA applicants and holders should monitor for changes to RLD labeling: The sponsor […]
Taiwan Food and Drug Administration (TFDA) released guidelines for eCTD specification. Following countries such as the USA, EU, Japan, Australia, Canada and Switzerland, Taiwan will soon adopt the eCTD standard.
A meeting has been held by US-Food & Drug Administration for explaining the concept of new FDA form 3938 for the submission of Drug Master File to FDA. The agenda for the meeting was to explain the concept of Form 3938, the details of the form, purpose of the form, when should the form 3938 […]
Cross labeling guidance is in response to increasing requests from sponsors applying for oncology drugs intended to be used in combination regimens. The purpose of this guidance is to describe FDA’s current recommendations about including relevant information in labeling for oncology drugs approved for use in a combination regimen, including important considerations for cross labeling […]